Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
By Colin Kellaher
Pfizer has won Food and Drug Administration approval of Beqvez, a one-time gene therapy for certain patients with the inherited bleeding disorder hemophilia B.
The New York drugmaker on Friday said the approval covers the treatment of adults with moderate to severe hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and don't have neutralizing antibodies to adeno-associated virus serotype Rh74var.
Hemophilia B is a rare disorder that prevents normal blood clotting because of a deficiency in factor X that causes those with the disease to bleed more frequently and longer than others.
Pfizer said Beqvez is designed to enable people living with hemophilia B to produce factor IX themselves rather than the current standard of care, which requires regular intravenous infusions that are often administered multiple times a week or month.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 26, 2024 07:14 ET (11:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing